Docoh
Loading...

ALEC Alector

GRANT
Utility
Siglec transgenic mice and methods of use thereof
19 Oct 21
Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals.
Arnon Rosenthal, Seung-Joo Lee
Filed: 8 Dec 17
APP
Utility
ANTI-CD33 Antibodies and Methods of Use Thereof
14 Oct 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Patricia CULP, Helen LAM, Wei-Hsien HO, Leonard G. PRESTA, Arnon ROSENTHAL
Filed: 30 Aug 19
GRANT
Utility
Anti-CD33 antibodies and methods of use thereof
5 Oct 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate Monroe, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee, William Monteith, Herve Rhinn, Arnon Rosenthal
Filed: 11 Jun 16
APP
Utility
SIGLEC-9 Ecd Fusion Molecules and Methods of Use Thereof
16 Sep 21
The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.
Spencer Liang, Samuel Nalle, Jeonghoon Sun, Hua Long, Rashmi Bankoti
Filed: 3 Nov 20
APP
Utility
Anti-SIRP-Beta1 Antibodies and Methods of Use Thereof
9 Sep 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPβ1 polypeptide, e.g., a human SIRPβ1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Andrew Pincetic, Patricia Culp, Arnon Rosenthal
Filed: 28 Jun 19
APP
Utility
Anti-mertk Antibodies and Methods of Use Thereof
26 Aug 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.
Seung-Joo LEE, Spencer LIANG, Angie YEE, Marina ROELL, Arnon ROSENTHAL
Filed: 11 Dec 20
APP
Utility
ANTI-SIGLEC-7 Antibodies and Methods of Use Thereof
12 Aug 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Patricia CULP, Seung-Joo LEE, Helen LAM, Wei-Hsien HO, Arnon ROSENTHAL
Filed: 7 Jun 19
GRANT
Utility
Anti-TREM2 antibodies and methods of use thereof
10 Aug 21
The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2.
Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
Filed: 11 Apr 19
APP
Utility
ANTI-CD33 Antibodies and Methods of Use Thereof
13 May 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
Filed: 7 May 20
APP
Utility
Methods of Screening for Sortilin Binding Antagonists
29 Apr 21
The present disclosure provides methods of screening for a sortilin binding antagonist.
Arnon ROSENTHAL, Tina SCHWABE
Filed: 3 Nov 20
APP
Utility
ANTI-MS4A6A Antibodies and Methods of Use Thereof
29 Apr 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e.g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Arnon ROSENTHAL
Filed: 31 Jan 19
APP
Utility
Chimeric Receptors and Methods of Use Thereof
8 Apr 21
The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.
Arnon ROSENTHAL
Filed: 30 Nov 20
APP
Utility
ANTI-SIGLEC-9 Antibodies and Methods of Use Thereof
1 Apr 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
Filed: 10 Sep 20
APP
Utility
ANTI-MS4A4A Antibodies and Methods of Use Thereof
18 Mar 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Jeonghoon SUN, Wei-Hsien HO, Muhammad A. ALHAWAGRI, Philip Ling KONG, Herve RHINN, Hua LONG, Karpagam SRINIVASAN, Ananya MITRA, Daniel P. BERMINGHAM, Klaus-Dieter HEGER, Santiago Viveros SALAZAR, Francesca CIGNARELLA, Ilaria TASSI, Tina SCHWABE, Angie Grace YEE, Arnon ROSENTHAL
Filed: 30 Jul 20
APP
Utility
ANTI-MS4A4A Antibodies and Methods of Use Thereof
11 Feb 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
Filed: 31 Jan 19
APP
Utility
ANTI-SIGLEC-5 Antibodies and Methods of Use Thereof
21 Jan 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
Filed: 15 May 18
GRANT
Utility
Chimeric receptors and methods of use thereof
28 Dec 20
The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.
Arnon Rosenthal
Filed: 25 Apr 17
APP
Utility
Methods of Use of Anti-sortilin Antibodies
16 Dec 20
The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Herve RHINN
Filed: 9 Jun 20
GRANT
Utility
Methods of screening for sortilin binding antagonists
30 Nov 20
The present disclosure provides methods of screening for a sortilin binding antagonist.
Arnon Rosenthal, Tina Schwabe
Filed: 6 Apr 16
APP
Utility
ANTI-TMEM106B Antibodies and Methods of Use Thereof
28 Oct 20
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Eric BROWN, Tina SCHWABE, Angie YEE, Herve RHINN
Filed: 20 Dec 18
Patents are sorted by USPTO publication date, most recent first